Annual Report 2019
Division of Screening Assessment and Management
Tomio Nakayama, Hirokazu Takahashi, Akiko Matsumoto, Emiko Ando, Kanako Kono, Noriaki Takahashi, Kanoko Matsushima, Akiko Totake, Asako Kowada, Nao Ida, Rie Haruta
Introduction
The Division of Screening Assessment and Management has conducted studies on the assessment and management of screening programs, particularly those of nationwide programs, and on other issues relevant to cancer screening.
In addition, the most important mission of the Center for Public Health Sciences in terms of screening is the central activity of assessing and managing cancer screening at the national level, which is closely related to the pillars in the Individual Targets for Cancer Screening in the Basic Cancer Control Plan. Thus, our division has developed and updated screening guidelines (Cancer Screening Assessment), and established quality assurance systems for the screening programs (Cancer Screening Management).
The Team and What We Do
Our division consists of two teams according to the activities they are in charge of. One is the activity for assessing cancer screening, and the other for Quality Assurance. T. Nakayama is the head of the former team, and K. Kono, N. Takahashi and E. Ando manage the prospective studies for evaluation of cancer screening and A. Totake, A. Kowada, N. Ida and R. Haruta assist the studies. T Nakayama and K. Matsushima manage the development of cancer screening guidelines. H. Takahashi is involved in the latter team.
Research activities
1. Studies to evaluate the effectiveness of cancer screening
The randomized controlled trial (Akita study) to evaluate screening for colon cancer using total colonography finished recruiting volunteers at end of March 2017 (a total of 9,751 persons). A follow up study is ongoing using a demographic survey and regional cancer registry. A cohort study to evaluate screening for cervical cancer using an HPV test and Pap smear has passed the midpoint of the total study period to perform third round screening for participants registered in 2014. We established a follow-up team for an ongoing randomized controlled trial (JEC study) of lung cancer screening using low-dose CT, and started organizing data on up to 10,000 persons and detailed examination results and prognostic information.
2. Development of cancer screening guidelines and related issues
The guidelines of cervical cancer screening have been renewed. Both a Pap smear and HPV test were recommended as a grade A recommendation. We examined the upper age limit for colorectal cancer screening using a microsimulation model, and showed that the increase in harm was more pronounced than the benefit in screening persons aged over 80 years old.
3. Quality assurance of cancer screening
In population-based screening, we have started to consider setting a baseline value by estimating the prevalence rate of cancer screenees, as process indicators have been improving in cancer screening at workplaces. We have developed and validated a logic for identifying cancer patients based on receipt to ascertain the number of cancers detected in screening at workplaces. We conducted interview surveys with more than 10 insurer groups about the problems of cancer screening at workplaces.
Future prospects
In screening assessment studies, progress management will continue until the follow-up is completed with the goal of completing large scale prospective studies. The colorectal cancer screening guidelines will be updated until 2021. In quality control, we will release a new baseline value of process indicators during FY2020.
List of papers published in 2019
Journal
1. Masaoka H, Matsuo K, Oze I, Ito H, Naito M, Wada K, Nagata C, Nakayama T, Kitamura Y, Sadakane A, Tamakoshi A, Tsuji I, Sugawara Y, Sawada N, Mizoue T, Inoue M, Tanaka K, Tsugane S, Shimazu T. Alcohol Drinking and Bladder Cancer Risk From a Pooled Analysis of Ten Cohort Studies in Japan. J Epidemiol, 30:309-313, 2020
2. Saito H, Kudo SE, Takahashi N, Yamamoto S, Kodama K, Nagata K, Mizota Y, Ishida F, Ohashi Y. Efficacy of screening using annual fecal immunochemical test alone versus combined with one-time colonoscopy in reducing colorectal cancer mortality: the Akita Japan population-based colonoscopy screening trial (Akita pop-colon trial). Int J Colorectal Dis, 35:933-939, 2020
3. Liu R, Kitamura Y, Kitamura T, Sobue T, Sado J, Sugawara Y, Matsuo K, Nakayama T, Tsuji I, Ito H, Suzuki T, Katanoda K, Tominaga S. Reproductive and lifestyle factors related to breast cancer among Japanese women: An observational cohort study. Medicine (Baltimore), 98:e18315, 2019
4. Sado J, Kitamura T, Kitamura Y, Liu R, Ando E, Sobue T, Sugawara Y, Matsuo K, Nakayama T, Tsuji I, Ito H, Suzuki T, Katanoda K, Tominaga S. Coffee Consumption and All-Cause and Cardiovascular Mortality - Three-Prefecture Cohort in Japan. Circ J, 83:757-766, 2019
5. Sagawa M, Machii R, Nakayama T, Sugawara T, Ishibashi N, Mitomo H, Kondo T, Tabata T. The Prefectural Participation Rates of Lung Cancer Screening Had a Negative Correlation with the Lung Cancer Mortality Rates. Asian Pac J Cancer Prev, 20:855-861, 2019
6. Yagi A, Ueda Y, Ikeda S, Sekine M, Nakayama T, Miyagi E, Enomoto T. Evaluation of future cervical cancer risk in Japan, based on birth year. Vaccine, 37:2889-2891, 2019
7. Yagi A, Ueda Y, Kakuda M, Tanaka Y, Ikeda S, Matsuzaki S, Kobayashi E, Morishima T, Miyashiro I, Fukui K, Ito Y, Nakayama T, Kimura T. Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry. Cancer Res, 79:1252-1259, 2019
8. Fukui K, Ito Y, Nakayama T. Trends and projections of cancer mortality in Osaka, Japan from 1977 to 2032. Jpn J Clin Oncol, 49:383-388, 2019
9. Terasawa T, Hamashima C, Kato K, Miyashiro I, Yoshikawa T, Takaku R, Nishida H. Helicobacter pylori eradication treatment for gastric carcinoma prevention in asymptomatic or dyspeptic adults: systematic review and Bayesian meta-analysis of randomised controlled trials. BMJ Open, 9:e026002, 2019
10. Taniguchi M, Ueda Y, Yagi A, Ikeda S, Endo M, Tomimatsu T, Nakayama T, Sekine M, Enomoto T, Kimura T. Cervical cancer screening rate differs by HPV vaccination status: An interim analysis. Vaccine, 37:4424-4426, 2019
11. Tanaka Y, Ueda Y, Kakuda M, Yagi A, Okazawa A, Egawa-Takata T, Matsuzaki S, Kobayashi E, Yoshino K, Fukui K, Ito Y, Nakayama T, Kimura T. Trends in incidence and long-term survival of Japanese women with vulvar cancer: a population-based analysis. Int J Clin Oncol, 24:1137-1142, 2019
12. Oze I, Ito H, Nishino Y, Hattori M, Nakayama T, Miyashiro I, Matsuo K, Ito Y. Trends in Small-Cell Lung Cancer Survival in 1993-2006 Based on Population-Based Cancer Registry Data in Japan. J Epidemiol, 29:347-353, 2019